The FDA has granted approval for the medication sotatercept

The US Food and Drug Administration (FDA) has granted approval for the medication sotatercept, a significant milestone in the treatment of pulmonary arterial hypertension (PAH).

Sotatercept, which will be marketed under the brand name Winrevair® by Merck, is a first-of-its-kind drug designed to target the underlying biology of PAH by trapping proteins called activins that are overproduced in individuals with the condition.

Read more about this groundbreaking development in articles from CNN, FDA, and Merck.